(Q34332708)

1 August 2017

1 reference

title

Vaccines for the prevention of HIV-1 disease (English)

1 reference

1 August 2017

prevention of HIV/AIDS

0 references

1

Mascola JR

1 reference

1 August 2017

Nabel GJ

2

1 reference

1 August 2017

1 August 2001

1 reference

Current Opinion in Immunology

1 August 2017

1 reference

1 August 2017

13

1 reference

1 August 2017

4

1 reference

1 August 2017

489-495

1 reference

Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Immune control of HIV-1 after early treatment of acute infection

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Viremia control following antiretroviral treatment and therapeutic immunizationduring primary SIV251 infection of macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Control of SIV rebound through structured treatment interruptions during early infection

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

A Phase II Study of Two HIV Type 1 Envelope Vaccines, Comparing Their Immunogenicity in Populations at Risk for Acquiring HIV Type 1 Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1(SF-2) recombinant GP120.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Presentation of SIVgag to monkey T cells using dendritic cells transfected with a recombinant adenovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Development of a preventive vaccine for Ebola virus infection in primates

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: stimulation of humoral, mucosal, and cellular immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

HIV-1 DNA vaccines and chemokines.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: functional complementation of specific defects in gp120 and gp41.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Vaccination with Rev and Tat against AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900246-6

7 January 2021

10.1016/S0952-7915(00)00246-6

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11498307